MX2020003810A - Vacuna contra la periodontitis y composiciones relacionadas y metodos de uso. - Google Patents

Vacuna contra la periodontitis y composiciones relacionadas y metodos de uso.

Info

Publication number
MX2020003810A
MX2020003810A MX2020003810A MX2020003810A MX2020003810A MX 2020003810 A MX2020003810 A MX 2020003810A MX 2020003810 A MX2020003810 A MX 2020003810A MX 2020003810 A MX2020003810 A MX 2020003810A MX 2020003810 A MX2020003810 A MX 2020003810A
Authority
MX
Mexico
Prior art keywords
antigen sequence
sequence
rgpa
gingipain
immunogenic
Prior art date
Application number
MX2020003810A
Other languages
English (en)
Inventor
Jeffery Fairman
Original Assignee
Vaxcyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxcyte Inc filed Critical Vaxcyte Inc
Publication of MX2020003810A publication Critical patent/MX2020003810A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/0216Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/542Mucosal route oral/gastrointestinal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/543Mucosal route intranasal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proveen una composición inmunogenica, una formulación de vacuna periodontal que contiene la composición inmunogenica y métodos para tratar o prevenir la enfermedad periodontal, donde los métodos implican la administración de una cantidad inmunológicamente eficaz de la composición o la formulación de la vacuna a un sujeto; la composición inmunogenica contiene al menos un polipeptido que comprende: una secuencia de antígeno Mfa1 que es sustancialmente homologa a una secuencia de aminoacidos inmunogenica de una proteína fimbrilina de Mfa1 de una bacteria Porphyromona; y una secuencia de antígeno HA1, una secuencia de antígeno HA2 o tanto una secuencia de antígeno HA1 como una secuencia de antígeno HA2, en donde la secuencia de antígeno HA1 es sustancialmente homologa a una secuencia de aminoácidos inmunogenica de un dominio 1 de hemaglutinina de gingipain RgpA contenido en una proteína gingipain RgpA de una bacteria Porphyromona y la secuencia de antígeno HA2 es sustancialmente homologa a una secuencia de aminoácidos inmunogenica de un dominio 2 de hemaglutinina de gingipain RgpA contenido en una proteína gingipain RgpA de una bacteria Porphyromona.
MX2020003810A 2017-10-12 2018-10-11 Vacuna contra la periodontitis y composiciones relacionadas y metodos de uso. MX2020003810A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762571582P 2017-10-12 2017-10-12
PCT/US2018/055496 WO2019075260A1 (en) 2017-10-12 2018-10-11 VACCINE AGAINST PERIODONTITIS AND ASSOCIATED COMPOSITIONS AND METHOD OF USE

Publications (1)

Publication Number Publication Date
MX2020003810A true MX2020003810A (es) 2020-08-13

Family

ID=64110091

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003810A MX2020003810A (es) 2017-10-12 2018-10-11 Vacuna contra la periodontitis y composiciones relacionadas y metodos de uso.

Country Status (14)

Country Link
US (2) US10835590B2 (es)
EP (1) EP3694547A1 (es)
JP (2) JP7258870B2 (es)
KR (2) KR102530966B1 (es)
CN (1) CN111225684A (es)
AU (1) AU2018347511A1 (es)
CA (1) CA3078630A1 (es)
EA (1) EA202090908A1 (es)
IL (1) IL273690A (es)
MA (1) MA50363A (es)
MX (1) MX2020003810A (es)
PH (1) PH12020550239A1 (es)
SG (1) SG11202003147XA (es)
WO (1) WO2019075260A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10835590B2 (en) 2017-10-12 2020-11-17 Vaxcyte, Inc. Periodontitis vaccine and related compositions and methods of use
CN116751292B (zh) * 2023-07-31 2024-05-14 河南大学 牙龈卟啉单胞菌Mfa1单克隆抗体及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59128338A (ja) 1982-12-08 1984-07-24 Kitasato Inst:The 歯周炎予防用ワクチン及びその製法
NZ267291A (en) 1993-05-28 1997-09-22 Chiron Corp Peptide inhibitors of urokinase receptor activity
AUPN627595A0 (en) 1995-10-30 1995-11-23 University Of Melbourne, The Diagnostics and treatments of periodontal disease
WO1997034629A1 (en) 1996-03-22 1997-09-25 University Of Georgia Research Foundation, Inc. Immunogenic compositions comprising porphyromonas gingivalis peptides and methods
US6833262B1 (en) 1999-04-21 2004-12-21 University Of Georgia Research Foundation, Inc. Polypeptide having amidolytic activity for a serpin
AUPQ065299A0 (en) * 1999-05-28 1999-06-24 University Of Sydney, The A method of prophylaxis and treatment and agents useful for same
AUPQ485999A0 (en) * 1999-12-24 2000-02-03 Csl Limited P. gingivalis antigenic composition
US7378101B2 (en) * 2001-12-21 2008-05-27 Pfizer, Inc. Vaccine for periodontal disease
GB0411150D0 (en) 2004-05-19 2004-06-23 Queen Mary & Westfield College Vaccine
BR112012002429A2 (pt) 2009-08-02 2016-11-08 Sanofi Pasteur Ltd polipeptídeos de porphyromonas gingivalis
EP2533794A4 (en) * 2010-02-12 2014-04-23 Univ Sydney PROTEIN DOMAINS AND ASSOCIATED USES
WO2011130544A2 (en) 2010-04-14 2011-10-20 Sutro Biopharma, Inc. Monitoring a dynamic system by liquid chromatography-mass spectrometry
PL2906592T3 (pl) 2012-10-12 2019-07-31 Sutro Biopharma, Inc. Proteolityczna inaktywacja wybranych białek w ekstraktach bakteryjnych dla ulepszonej ekspresji
EP3365027B1 (en) * 2015-10-14 2022-03-30 Research Institute at Nationwide Children's Hospital Hu specific antibodies and their use in inhibiting biofilm
US10835590B2 (en) 2017-10-12 2020-11-17 Vaxcyte, Inc. Periodontitis vaccine and related compositions and methods of use

Also Published As

Publication number Publication date
US20240226259A9 (en) 2024-07-11
CA3078630A1 (en) 2019-04-18
JP2020536925A (ja) 2020-12-17
AU2018347511A8 (en) 2020-06-11
MA50363A (fr) 2020-08-19
US10835590B2 (en) 2020-11-17
US20240131134A1 (en) 2024-04-25
AU2018347511A1 (en) 2020-05-21
KR102530966B1 (ko) 2023-05-15
WO2019075260A1 (en) 2019-04-18
JP2023098935A (ja) 2023-07-11
JP7258870B2 (ja) 2023-04-17
PH12020550239A1 (en) 2021-02-15
US20210361756A1 (en) 2021-11-25
SG11202003147XA (en) 2020-05-28
IL273690A (en) 2020-05-31
CN111225684A (zh) 2020-06-02
US11701414B2 (en) 2023-07-18
EA202090908A1 (ru) 2020-10-29
EP3694547A1 (en) 2020-08-19
BR112020006500A2 (pt) 2020-10-13
US20190192645A1 (en) 2019-06-27
KR20230066660A (ko) 2023-05-16
KR20200070302A (ko) 2020-06-17

Similar Documents

Publication Publication Date Title
EA201692315A1 (ru) Составы и способы обработки кератина
UY39060A (es) Composiciones y métodos para prevenir y tratar la infección por coronavirus - vacunas sars-cov-2
CL2019003264A1 (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas. (divisional solicitud 201703151)
BR112017000313A2 (pt) sistema para o fornecimento de uma composição para tratamento bucal, composição para tratamento bucal, método para administrar uma composição para tratamento bucal
AR081809A1 (es) Composiciones farmaceuticas que comprenden un polipeptido que comprende al menos un motivo cxxc y antigenos heterologos y usos de las mismas
PE20110023A1 (es) Composiciones inmunogenicas de antigenos de staphylococcus aureus
CL2018003178A1 (es) Composición farmacéutica
CL2020001821A1 (es) Formulación de adenovirus del grupo b.
AR108631A1 (es) Formulación de neurotoxinas
BR112022005687A2 (pt) Vacinas contra o hbv e métodos para tratar o hbv
MX2020003810A (es) Vacuna contra la periodontitis y composiciones relacionadas y metodos de uso.
EA202091769A1 (ru) Вакцины против вируса гриппа и пути их применения
CO2022012272A2 (es) Vacunas contra el coronavirus y métodos de uso
EA202191515A1 (ru) Фармацевтическая композиция, содержащая апиксабан
BR112012030619A2 (pt) concentração de antígenos de vacina influenza sem liofilização.
EA202191145A1 (ru) Вакцина виб 4/91 с гетерологичным шиповидным белком
BRPI0808599A2 (pt) "ácido nucléico, vacina, composição farmacêutica, uso de um ácido nucléico e método para estimular uma imunoresposta versus um epítopo das células t"
BR112015013625A2 (pt) adjuvante de vacinação, preparação e vacinas contendo o mesmo
BR112022003639A2 (pt) Agente bioestimulante para tratamento de plantas e/ou de sementes de plantas
CL2023001816A1 (es) Parapoxvirus modificado que tiene inmunogenicidad incrementada
EA202091563A1 (ru) Человеческие антитела к гемагглютинину вируса гриппа
AR083006A1 (es) Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
CL2020002519A1 (es) Composiciones de erenumab y usos de las mismas
AR111380A1 (es) Tratamiento para el asma con anticuerpo anti-tslp
AR107295A1 (es) Administración intradérmica de una composición de inmunoglobulina g